A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2004
11/18/2004	WO2004098586A1 Use of phenoxyacetic acid derivatives for treating hyperactive bladder
11/18/2004	WO2004098585A1 Use of kynurenine-3-hydroxylase inhibitors for the preparation of medicaments for the treatment of l-dopa induced movement disorders, dyskinesias, drug addiction, pain and cataract
11/18/2004	WO2004098583A1 Combination comprising s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and an hmg coa reductase inhibitor
11/18/2004	WO2004098582A2 Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions
11/18/2004	WO2004098581A2 Oral spray to reduce cold symptoms and duration of same
11/18/2004	WO2004098579A2 Combination of a glycine/nmda antagonist and a tachykinin nk-1 receptor antagonist for use in the treatment of neurodegeneration
11/18/2004	WO2004098578A2 Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
11/18/2004	WO2004098577A2 Dosage form containing (s)-pantoprazole as active ingredient
11/18/2004	WO2004098576A1 Abuse-resistant transdermal dosage form
11/18/2004	WO2004098575A1 Ultraviolet-shielding type patch
11/18/2004	WO2004098572A1 Biphasic release of glipizide from monocompartment osmotic dosage form
11/18/2004	WO2004098571A1 Cold remedy composition comprising zinc salts
11/18/2004	WO2004098570A1 Nanoparticulate bioactive agents
11/18/2004	WO2004098569A1 Micelle delivery system loaded with a pharmaceutical agent
11/18/2004	WO2004098568A2 Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
11/18/2004	WO2004098567A2 Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
11/18/2004	WO2004098566A2 Chewable lozenge cold remedy composition and method for making same
11/18/2004	WO2004098565A2 Implantable controlled release bioactive agent delivery device
11/18/2004	WO2004098564A2 Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide
11/18/2004	WO2004098562A2 Controlled release solid dosage nifedipine formulations
11/18/2004	WO2004098561A2 Particulate materials
11/18/2004	WO2004098543A2 Use of oligogalacturonide-type oligosaccharides in cosmetic, food or dermatological compositions in order to stimulate epidermal cell differentiation
11/18/2004	WO2004098538A2 Nitrosated and nitrosylated compounds, compositions and methods of use
11/18/2004	WO2004098531A2 Increased transduction using abc transporter substrates and/or inhibitors
11/18/2004	WO2004098528A2 Pyrazole-amine compounds useful as kinase inhibitors
11/18/2004	WO2004098527A2 Methods of treating neuralgic pain
11/18/2004	WO2004098525A2 Uses of ion channel modulating compounds
11/18/2004	WO2004098520A2 Compounds and compositions as protein kinase inhibitors
11/18/2004	WO2004098519A2 Ginkgo biloba extract as a treatment for therapeutic induced neurotoxicity
11/18/2004	WO2004098518A2 Pyrazole-amide compounds useful as kinase inhibitors
11/18/2004	WO2004098517A2 Methods of hormonal treatment utilizing extended cycle contraceptive regimens
11/18/2004	WO2004098516A2 Cyclic derivatives as modulators of chemokine receptor activity
11/18/2004	WO2004098512A2 Malonamides and malonamide derivatives as modulators of chemokine receptor activity
11/18/2004	WO2004098510A2 Cystic fibrosis therapy
11/18/2004	WO2004098507A2 1,3 aclyated 24-keto-vitamin d3 compounds and methods of use thereof
11/18/2004	WO2004098506A2 Treatment for age-related macular degeneration
11/18/2004	WO2004098505A2 Attenuation of ischemia/reperfusion injury
11/18/2004	WO2004098504A2 Antitumor 2-aminocarbonyl-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines and methods of treating tumors
11/18/2004	WO2004098501A2 Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
11/18/2004	WO2004098500A2 CARBACEPHEM ss-LACTAM ANTIBIOTICS
11/18/2004	WO2004098498A2 Indole acetic acid derivatives and their use as pharmaceutical agents
11/18/2004	WO2004098496A2 Compounds for the treatment of metabolic disorders
11/18/2004	WO2004098495A2 Medical devices and methods for inhibiting proliferation of smooth muscle cells
11/18/2004	WO2004098494A2 Compounds, compositions, and methods
11/18/2004	WO2004098491A2 METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
11/18/2004	WO2004087740A3 Preserved and stable compositions containing peptide copper complexes and methods related thereto
11/18/2004	WO2004087729A9 Degradation products of azithromycin, and methods for their identification
11/18/2004	WO2004087157A3 Combination of gh secretagogues and pde4 inhibitors for the treatment of alzheimer's disease
11/18/2004	WO2004082628A3 Improved bioavailability and improved delivery of acidic pharmaceutical drugs
11/18/2004	WO2004082582A3 Use of diazoxide in the treatment of ischemia retinae
11/18/2004	WO2004078205A8 Targeting a protein prc1 for the treatment of pancreatic cancer
11/18/2004	WO2004078127A3 Continuous delivery methods for treating hepatitis virus infection
11/18/2004	WO2004078102A3 Sterilization of beclomethasone drug particles for pulmonary delivery
11/18/2004	WO2004075865A3 Selective modulation of tlr-mediated biological activity
11/18/2004	WO2004074246A3 Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
11/18/2004	WO2004073632A3 Rapid absorption selective 5-ht agonist formulations
11/18/2004	WO2004073627A3 Novel therapeutic method and compositions for topical administration
11/18/2004	WO2004073593A3 Use of acylated aminopropanediols and sulphur and nitrogen analogues of same for different therapeutic applications
11/18/2004	WO2004071486B1 Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
11/18/2004	WO2004071421A3 Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds
11/18/2004	WO2004071381A3 Drugs containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds
11/18/2004	WO2004069157A3 Combinational use of long-acting and short-acting anti-histamines for ocular allergies
11/18/2004	WO2004066983A3 Controlled release of highly soluble agents
11/18/2004	WO2004066725A3 Avermectin- and avermectin monosaccharide derivatives substituted in the 4”- or 4’-position having pesticidal properties
11/18/2004	WO2004063160A8 Novel quaternary ammonium salt compound having antibacterial activity and process for producing the same
11/18/2004	WO2004054515A3 Thrombopoietin mimetics
11/18/2004	WO2004048591A3 Methods for cohort selection and longevity studies
11/18/2004	WO2004046223A3 Polyionene polymers with hydrolyzable linkages
11/18/2004	WO2004043350A3 PURIFIED COMPOUNDS THAT INHIBIT INTRACELLULAR α4/PAXILLIN BINDING
11/18/2004	WO2004037997A3 Fragments and activity of rel protein in m. tuberculosis adn other uses thereof
11/18/2004	WO2004037783B1 Treatment of cognitive impairment using a selective dopamine d1 receptor agonist
11/18/2004	WO2004036181A3 Method of treating neurological diseases and disorders
11/18/2004	WO2004035132A3 Compositions and methods for inducing osteogenesis
11/18/2004	WO2004035083A3 Compositions for the treatment of autoimmune disorders
11/18/2004	WO2004028454A3 1, 3, 5-triazines for treatment of viral diseases
11/18/2004	WO2004002528A9 Compositions and methods for therapeutic treatment
11/18/2004	WO2003087021A8 Nanoparticle delivery systems and methods of use thereof
11/18/2004	WO2003084312A3 Identification and characterization of an anthocyanin mutant (ant1) in tomato
11/18/2004	WO2003075829A3 Tasteless directly compressible fast-dissolving complexes and pharmaceutical formulations thereof
11/18/2004	WO2003038043A3 Combinations of dr5 antibody and other therapeutic agents
11/18/2004	WO2003037913A3 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/18/2004	WO2003037900A3 Pyrazolopyrimidines
11/18/2004	WO2002090499A3 ss-AMYLOID PEPTIDE-BINDING PROTEINS AND POLYNUCLEOTIDES ENCODING THE SAME
11/18/2004	US20040231005 Comprises proteolytic enzymes for use as tools to identify modulators for treatment and prevention of gastrointestinal, cell proliferative and inflammatory diseases
11/18/2004	US20040230261 Method and assembly for treating pain of liquid nitrogen therapy
11/18/2004	US20040230257 Enhanced bioavailability of nutrients, pharmaceutical agents, and other bioactive substances through laser resonant homogenization or modification of molecular shape or crystalline form
11/18/2004	US20040230067 Using alpha beta unsaturated cyclohexanone derivative as inductors; higher recognizing property of targeted acceptor substance
11/18/2004	US20040230065 Process for the preparation of 5-substituted isobenzofurans
11/18/2004	US20040230064 Novel labeled resiniferatoxin derivatives
11/18/2004	US20040230051 Comprises nucleotide sequences coding b lymphocyte antigens for use as tool in prevention and treatment of cell proliferative disorders; immunotherapy
11/18/2004	US20040230035 protease/thrombin inhibitors
11/18/2004	US20040229960 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
11/18/2004	US20040229957 cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia
11/18/2004	US20040229956 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
11/18/2004	US20040229954 Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt
11/18/2004	US20040229953 Process for preparing highly water soluble double salts of hydroxycitric acid particularly alkali and alkaline earth metal double salts
11/18/2004	US20040229951 carboxy amines
11/18/2004	US20040229950 Method and composition with conjugated linoleic acid esters
11/18/2004	US20040229949 New 3-aryl propionic acid derivatives and analogs
11/18/2004	US20040229948 Administering phenyl butyrate compound or a salt, derivative or metabolite of phenyl butyrate in a pharmaceutically acceptable vehicle to prevent loss of brain and mental function associated with disorders of liver function

1 ... 4886 4887 4888 4889 4890 4891 4892 4893 4894 4895 4896 4897 4898 4899 4900 4901 4902 4903 4904 4905 4906 ... 7860